CR20210530A - Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona - Google Patents
Compuestos de 4h-pirrolo[3,2-c]piridin-4-onaInfo
- Publication number
- CR20210530A CR20210530A CR20210530A CR20210530A CR20210530A CR 20210530 A CR20210530 A CR 20210530A CR 20210530 A CR20210530 A CR 20210530A CR 20210530 A CR20210530 A CR 20210530A CR 20210530 A CR20210530 A CR 20210530A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- pyrrolo
- pyridin
- formula
- pharmaceuticals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de la fórmula (I), procesos para su producción y uso como preparados farmacológicos. <img src="data:image/png;base64,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 (***)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962838051P | 2019-04-24 | 2019-04-24 | |
US201962940036P | 2019-11-25 | 2019-11-25 | |
PCT/EP2020/061176 WO2020216781A1 (en) | 2019-04-24 | 2020-04-22 | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210530A true CR20210530A (es) | 2021-12-23 |
Family
ID=70456765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210530A CR20210530A (es) | 2019-04-24 | 2020-04-22 | Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona |
Country Status (20)
Country | Link |
---|---|
US (1) | US20220298157A1 (es) |
EP (1) | EP3959211A1 (es) |
JP (1) | JP2022532850A (es) |
KR (1) | KR20220004103A (es) |
CN (3) | CN114127064B (es) |
AU (1) | AU2020262221A1 (es) |
BR (1) | BR112021019998B1 (es) |
CA (1) | CA3137218A1 (es) |
CL (1) | CL2021002770A1 (es) |
CO (1) | CO2021014022A2 (es) |
CR (1) | CR20210530A (es) |
EC (1) | ECSP21077614A (es) |
IL (1) | IL287390A (es) |
JO (1) | JOP20210285A1 (es) |
MA (1) | MA55751A (es) |
MX (1) | MX2021012987A (es) |
PE (1) | PE20220254A1 (es) |
SG (1) | SG11202111304UA (es) |
TW (1) | TW202106683A (es) |
WO (1) | WO2020216781A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019081486A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | 4H-PYRROLO [3,2-C] PYRIDIN-4-ONE DERIVATIVES |
WO2022033416A1 (zh) * | 2020-08-10 | 2022-02-17 | 上海和誉生物医药科技有限公司 | 作为egfr抑制剂的稠环化合物及其制备方法和应用 |
EP4217070A1 (en) * | 2020-09-23 | 2023-08-02 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
WO2022094271A1 (en) * | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
WO2022101184A1 (en) * | 2020-11-11 | 2022-05-19 | Bayer Aktiengesellschaft | N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer |
US20220387405A1 (en) * | 2021-05-06 | 2022-12-08 | Celgene Corporation | Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carboxamide |
WO2023183601A1 (en) * | 2022-03-24 | 2023-09-28 | Scorpion Therapeutics, Inc. | Methods of synthesizing egfr inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
US7211573B2 (en) | 2004-12-08 | 2007-05-01 | Hoffmann-La Roche Inc. | Malonamide derivatives |
DE102006033140A1 (de) | 2006-07-18 | 2008-01-24 | Merck Patent Gmbh | Aminoindazolharnstoffderivate |
EP2151431A4 (en) | 2007-04-27 | 2010-04-21 | Sumitomo Chemical Co | AMIDE COMPOUND AND USE THEREOF |
BRPI0814777A2 (pt) | 2007-08-08 | 2015-03-03 | Glaxosmithkline Llc | Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica. |
TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
JP5789602B2 (ja) * | 2009-06-15 | 2015-10-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用 |
EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
WO2015022073A1 (en) | 2013-08-13 | 2015-02-19 | Grünenthal GmbH | Annelated pyrroles and their use as crac inhibitors |
CA2952307A1 (en) | 2014-06-17 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
JP2017538697A (ja) | 2014-12-08 | 2017-12-28 | バイエル ファーマ アクチエンゲゼルシャフト | 新規なアリール−シアノグアニジン化合物 |
WO2016100166A1 (en) | 2014-12-15 | 2016-06-23 | Bristol-Myers Squibb Company | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS |
AU2016212230B2 (en) | 2015-01-28 | 2019-09-19 | Bayer Pharma Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
-
2020
- 2020-04-22 EP EP20721196.2A patent/EP3959211A1/en active Pending
- 2020-04-22 MA MA055751A patent/MA55751A/fr unknown
- 2020-04-22 KR KR1020217037778A patent/KR20220004103A/ko unknown
- 2020-04-22 AU AU2020262221A patent/AU2020262221A1/en active Pending
- 2020-04-22 JO JOP/2021/0285A patent/JOP20210285A1/ar unknown
- 2020-04-22 PE PE2021001760A patent/PE20220254A1/es unknown
- 2020-04-22 CN CN202080031189.4A patent/CN114127064B/zh active Active
- 2020-04-22 US US17/605,975 patent/US20220298157A1/en active Pending
- 2020-04-22 JP JP2021563175A patent/JP2022532850A/ja active Pending
- 2020-04-22 CN CN202311714944.0A patent/CN117946100A/zh active Pending
- 2020-04-22 CR CR20210530A patent/CR20210530A/es unknown
- 2020-04-22 SG SG11202111304UA patent/SG11202111304UA/en unknown
- 2020-04-22 TW TW109113538A patent/TW202106683A/zh unknown
- 2020-04-22 CA CA3137218A patent/CA3137218A1/en active Pending
- 2020-04-22 CN CN202311716707.8A patent/CN117986251A/zh active Pending
- 2020-04-22 MX MX2021012987A patent/MX2021012987A/es unknown
- 2020-04-22 WO PCT/EP2020/061176 patent/WO2020216781A1/en active Application Filing
- 2020-04-22 BR BR112021019998-5A patent/BR112021019998B1/pt active IP Right Grant
-
2021
- 2021-10-19 IL IL287390A patent/IL287390A/en unknown
- 2021-10-19 EC ECSENADI202177614A patent/ECSP21077614A/es unknown
- 2021-10-20 CO CONC2021/0014022A patent/CO2021014022A2/es unknown
- 2021-10-21 CL CL2021002770A patent/CL2021002770A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022532850A (ja) | 2022-07-20 |
CN117986251A (zh) | 2024-05-07 |
US20220298157A1 (en) | 2022-09-22 |
WO2020216781A1 (en) | 2020-10-29 |
EP3959211A1 (en) | 2022-03-02 |
SG11202111304UA (en) | 2021-11-29 |
CN114127064A (zh) | 2022-03-01 |
PE20220254A1 (es) | 2022-02-16 |
ECSP21077614A (es) | 2021-11-30 |
MX2021012987A (es) | 2022-04-01 |
CL2021002770A1 (es) | 2022-05-27 |
CA3137218A1 (en) | 2020-10-29 |
BR112021019998A2 (es) | 2021-12-07 |
AU2020262221A1 (en) | 2021-11-18 |
JOP20210285A1 (ar) | 2023-01-30 |
KR20220004103A (ko) | 2022-01-11 |
BR112021019998B1 (pt) | 2024-01-16 |
IL287390A (en) | 2021-12-01 |
CN114127064B (zh) | 2023-12-26 |
TW202106683A (zh) | 2021-02-16 |
CO2021014022A2 (es) | 2022-03-29 |
MA55751A (fr) | 2022-03-02 |
CN117946100A (zh) | 2024-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012987A (es) | Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona. | |
PH12017501340A1 (en) | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives | |
SA519402462B1 (ar) | مشتقات بيرولو[1، 2-b]بيريدازين | |
MX2021002978A (es) | Lactamas biciclicas y metodos de uso de las mismas. | |
TN2017000524A1 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
MY180903A (en) | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof | |
MY187449A (en) | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl | |
TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
AU2014230812A8 (en) | Process for making benzoxazepin compounds | |
PH12019502093A1 (en) | Novel ester compounds, method for the production thereof and use thereof | |
WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
PH12018501642B1 (en) | Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof | |
MX2016002718A (es) | Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). | |
TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
SG11201810725WA (en) | Novel β-lactamase inhibitors | |
MY185367A (en) | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof | |
WO2018193090A3 (en) | METHOD FOR PREPARING ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF | |
MX2020014276A (es) | Compuestos policiclicos como inhibidores de epoxido hidrolasa soluble. | |
MX2017006051A (es) | Derivados de 2,3-dihidro-tiazolo[3,2-a]piridin-5-ona, intermediarios de los mismos, y su uso como agentes antibacterianos. | |
MX2021004288A (es) | Nuevo proceso para la sintesis de derivados de piperazinil-etoxi-bromofenilo y su aplicacion en la produccion de compuestos que los contienen. | |
WO2018140738A8 (en) | Nrf2 activator | |
WO2020086650A3 (en) | Novel compounds | |
MX2019000984A (es) | Proceso para preparacion de indanonas. | |
EA202192881A1 (ru) | 4Н-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ |